ir.titanpharm.comInvestor Relations :: Titan Pharmaceuticals, Inc. (TTNP)

Navigate Titan Pharmaceuticals, Inc. Home About Overview Who We Are IP Portfolio Management Team Board of Directors Careers Technology Pipeline Kappa Opioid Receptor Agonist Nalmefene Implant News Overview Press Releases Events Presentations In the News Publications Posters Media Resources Investors Overview News / Events Company Information Stock Data SEC Filings Corporate Governance Contact Search Investor Relations Titan is advancing the treatment of select chronic diseases by developing therapeutics based on its proprietary long-term, continuous drug delivery platform, ProNeura®. ProNeura® Titan’s proprietary long-term, drug delivery platform provides continuous drug release and non-fluctuating medication levels over a period of six months or longer depending on drug characteristics. ProNeura products are subdermal implants that are intended for treating chronic diseases for which the maintenance of stable medication levels could offer advantages over other routes of administration. Home Investors Overview Overview Investors Navigate Investors Overview News / Events Company Information Stock Data SEC Filings Corporate Governance Email Alerts Tear Sheet Contacts RSS News Feed Latest News January 25, 2024 Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria Read Press Release Latest Financial Results 2023 Year End Results December 31, 2023 PDF HTML 10-K Filing HTML Financials ZIP XLS HTML XBRL Stock Quote Titan Pharmaceuticals, Inc. Nasdaq: TTNP Volume Day Low/High 52 Week Low/High Company Overview Titan is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides the potential for an efficacy and/or safety benefit. Titan’s lead product in development is an implant for the treatment of moderate-to severe-chronic pruritus. View Presentation Officers & Directors Executive Leadership Board of Directors David E. Lazar Interim Chairman of the Board of Directors and Chief Executive Officer David E. Lazar has served as the Chief Executive Officer of Custodian Ventures LLC, a company which specializes in assisting distressed public companies through custodianship, since February 2018, and Activist Investing LLC, an actively… View Full Bio Kate Beebe DeVarney, Ph.D. President and Chief Operating Officer Dr. DeVarney has served as a Director of Titan’s Board of Directors since 2019 and in October 2020, she became Titan’s President and Chief Operating Officer. She previously served as Chief Scientific Officer and has been with the… View Full Bio Kate Beebe DeVarney, Ph.D. President and Chief Operating Officer Dr. DeVarney has served as a Director of Titan’s Board of Directors since 2019 and in October 2020, she became Titan’s President and Chief Operating Officer. She previously served as Chief Scientific Officer and has been with the… View Full Bio Dato’ Seow Gim Shen Chairman of the Board of Directors Dato’ Seow Gim Shen obtained his Bachelor of Multimedia from Swinburne University of Technology in 2005. Dato’ Seow is an expert in IT development industry with more than 15 years of experience. Dato’ Seow also serves as the chairman… View Full Bio Avraham Ben-Tzvi Mr. Ben-Tzvi is the Founder of ABZ Law Office, a boutique Israeli law firm specializing in outsourced general counsel services for publicly traded as well as private companies and corporations, Investments & Securities Laws, Commercial… View Full Bio Eric Greenberg Mr. Greenberg has over 40 years of capital markets experience. As a trader and portfolio manager at hedge funds, his areas of expertise included the development of trading strategies, portfolio management and deal structuring. Mr.… View Full Bio David Natan Mr. Natan currently serves as President and Chief Executive Officer of Natan & Associates, LLC, a consulting firm offering chief financial officer services to public and private companies in a variety of industries, since 2007. In… View Full Bio Matthew C. McMurdo Mr. McMurdo currently serves as Managing Member of McMurdo Law Group, LLC, a corporate and securities law practice, since 2010. Previously, Mr. McMurdo was a Partner at Nannarone & McMurdo, LLP, a boutique law firm, from 2008 to 2010.… View Full Bio Brynner Chiam Brynner Chiam obtained his Bachelor of Business Studies (Accountancy) from Massey University in 1998. Since November 2020, he has held the position of vice president of finance and tax at Black Chamber Management Sdn Bhd where he oversees… View Full Bio © 2024 Titan Pharmaceuticals, Inc. All Rights Reserved. Privacy Policy Titan FCOI Policy Disclaimer...